On Monday, Leerink Partners adjusted their outlook on Elevance Health Inc (NYSE:ELV) shares, reducing the price target to $515 from the previous $620, while retaining an Outperform rating on the company's stock.
The adjustment follows the release of the company's third-quarter results, which highlighted significant challenges within the Medicaid segment due to redeterminations. These issues have led to Medicaid margins nearing zero percent, a concerning development for the healthcare provider.
The analyst from Leerink Partners noted that the mismatch between rates and patient acuity was a primary factor in the dwindling Medicaid margins. Despite these setbacks, the firm believes that the problems Elevance Health faces are solvable. However, the analyst anticipates that these pressures will continue throughout 2025, with the potential for negative Medicaid margins in the fourth quarter of 2024.
Elevance Health recently provided guidance for 2025, which seems to assume that Medicaid margins will hover around zero percent. This projection is intended to establish a baseline expectation for the upcoming year. The analyst expressed confidence in the management's ability to address and resolve these temporary issues, despite acknowledging that the next few quarters will present numerous challenges and reduce the clarity of future performance.
In the statement, the Leerink analyst conveyed a belief that the recent decline in Elevance Health's stock price was an overreaction. The firm's stance remains optimistic about the company's potential to overcome the current challenges, emphasizing the temporary nature of the issues at hand. The analyst concluded by reiterating the Outperform rating, signaling Leerink Partners' continued positive outlook on Elevance Health's stock.
In other recent news, Elevance Health Inc. has experienced a series of adjustments in its financial outlook. The company reported lower than expected Q3 2024 earnings, with an adjusted diluted EPS of $8.37, due to increased medical costs in its Medicaid business.
Consequently, Elevance adjusted its full-year outlook for adjusted EPS to approximately $33. Despite these changes, the company reported a 5% increase in total operating revenue, reaching $44.7 billion, and significant growth in commercial membership by nearly 600,000 year-over-year.
RBC Capital Markets and Truist Securities have both revised their price targets for Elevance, reducing them to $478 and $520 respectively, while maintaining positive ratings on the company's stock. These adjustments come in response to Elevance's updated financial outlook and the company's projection of a mid-single-digit EPS growth for 2025. Both firms, however, remain optimistic about the company's long-term prospects.
In addition to these developments, Elevance Health has announced the acquisition of CareBridge for home-based care. The company is projecting strong revenue growth in 2025 and beyond, anticipating growth in individual Medicare Advantage membership for 2025 and expecting continued growth in the commercial business. Despite the challenges in the Medicaid sector, Elevance Health remains committed to its long-term growth strategies.
InvestingPro Insights
Despite the recent challenges highlighted in Elevance Health's third-quarter results, InvestingPro data and tips offer additional context to the company's financial position. Elevance Health boasts a market capitalization of $99.91 billion, underscoring its significant presence in the Healthcare Providers & Services industry. The company's P/E ratio of 15.71 suggests a relatively reasonable valuation, especially when considering its adjusted P/E ratio of 13.58 for the last twelve months as of Q3 2024.
An InvestingPro Tip indicates that Elevance Health has raised its dividend for 14 consecutive years, demonstrating a commitment to shareholder returns even in challenging times. This is further supported by a current dividend yield of 1.51% and a robust dividend growth of 10.14% over the last twelve months. These factors may provide some reassurance to investors concerned about the recent stock price decline.
Another relevant InvestingPro Tip reveals that the company holds more cash than debt on its balance sheet, which could be crucial in navigating the current Medicaid margin pressures. This financial stability aligns with the analyst's confidence in management's ability to address the temporary issues facing the company.
For investors seeking a more comprehensive analysis, InvestingPro offers 11 additional tips that could provide valuable insights into Elevance Health's financial health and market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.